Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome 5/7/2024

Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performance 5/7/2024

AAV Manufacturing Takes Center Stage at ASGCT24 5/7/2024

ADC Therapeutics Posts Early Phase II Lymphoma Data for Zynlonta as Revenue Drops 5.8% 5/7/2024

Preliminary Findings Point to Low Risk of Secondary Cancers from CAR-T Therapies 5/7/2024

FDA Sets Date for Eli Lilly’s Donanemab Adcomm While Pondering Changes to Format 5/7/2024

Twelve years ago, cancer researchers at University of California San Diego identified a molecule that helps cancer cells survive by shuttling damaging inflammatory cells into tumor tissue. In new research, they show that the same molecule does the same thing in lung tissue infected with COVID-19 - and that the molecule can be suppressed with a repurposed cancer drug.

GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their respective mRNA development activities.

Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.

New UCSF study shows that suppressing a protein turns ordinary fat into a calorie burner and may explain why drug trials attempting the feat haven’t been successful.

Researchers at UC San Francisco have figured out how to turn ordinary white fat cells, which store calories, into beige fat cells that burn calories to maintain body temperature.

AstraZeneca's Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients.

Sipavibart is an investigational long-acting antibody designed to provide COVID-19 protection for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.

When a cancer cell doesn't respond to traditional therapies, doctors may turn to a sort of viral biological warfare, by deploying 'troops' in the form of viral agents that are specifically engineered to target and eliminate cancer cells. The mode of attack is to transform the tumor into an immunologically "hot" environment, making it more visible and recognisable to our immune system.

FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info 6/28/2024

Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate 6/28/2024

ICER Doubles Down on Critique of Lykos’ MDMA Therapy, Cites Data Concerns 6/28/2024

FDA Needs to Step Up As Use of Third-Party Manufacturers Leads to Rejections 6/28/2024

With Latest Expansion in Ohio, Resilience Can Best Serve Partners and Patients 6/28/2024

Illumina Reports $1.47B ‘Goodwill’ Impairment Charge After Grail Spinoff 6/28/2024

AbbVie Expands Immuno Portfolio With $250M Celsius Buy as Humira Hits Patent Cliff 6/28/2024

Antibiotic-resistant bacterial infections are becoming a major societal challenge. To solve this problem, researchers are working on new drugs that kill bacteria without developing resistance, and on new materials that prevent the formation of bacterial biofilms. The latter are the source of resistant variants but are notoriously difficult to remove. Recently, researchers from the Institute of Physical Chemistry, Polish Academy of Sciences have discovered that making the surface undulated can help limit the spread of resistant bacteria.

Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection 6/27/2024